ADMA
- ADMA Biologics, Inc.
()
Overview
Company Summary
ADMA Biologics, Inc. (ADMA) is a biopharmaceutical company that specializes in the development and commercialization of plasma-derived biologics. The company focuses on the production and distribution of polyclonal antibodies, which are produced by collecting human plasma, processing it, and extracting specific antibodies to treat diseases and medical conditions.
ADMA Biologics operates a state-of-the-art facility for plasma collection and has established a vertically integrated plasma fractionation and purification process. This enables them to manufacture high-quality, plasma-derived antibody products used for various medical purposes.
One of the main products offered by ADMA is BIVIGAM�, which is a plasma-based immune globulin (IVIG) utilized for the treatment of patients with primary immunodeficiency diseases (PIDD). This includes individuals with compromised immune systems due to genetic disorders or underlying medical conditions.
Additionally, ADMA works on developing other plasma-derived biologics that cater to therapeutic areas beyond immune deficiencies. They have ongoing research and development programs focused on developing products for infectious diseases, certain autoimmune disorders, and to support certain medical procedures.
ADMA Biologics aims to ensure the availability of reliable and high-quality biologics to meet the treatment needs of patients. Their primary goal is to advance patient care and improve outcomes by providing effective, safe, and appropriately dosed therapeutic solutions derived from human plasma.
Overall, ADMA Biologics plays a crucial role in the biopharmaceutical industry by utilizing the power of human plasma to develop essential and potentially life-saving therapies for various medical conditions.